Manufacturing licence negotiations for gene therapies for orphan diseases

Challenge A private biotech company developing gene therapy products for several orphan diseases was in the process of initiating CMC development for their pipeline products. In order to move...
Learn More

Market landscape exercise for three oncology university based therapeutics

Challenge A leading private US academic institution, recognizing the need to further develop early discoveries from the university in order to facilitate industry partnerships and clinical...
Learn More

Due diligence on generic therapeutic

Challenge A private investment firm was seeking an independent reality-check on a potential investment in a pharmaceutical company that had recently in-licensed a generic therapeutic asset. The firm...
Learn More

Competitive and market landscape for CAR T-cell therapy

Challenge A biotech company developing a platform technology to improve the safety of CAR T-cell therapies asked Alacrita to conduct a comprehensive competitive landscape to better understand the...
Learn More

New in-licensing opportunities in inflammation

Challenge A small molecule pharmaceutical incubator is using a novel and proprietary drug discovery and translational platform to develop first-in-class, small molecule therapeutics for the treatment...
Learn More

New in-licensing opportunities in oncology

Challenge A leading precision oncology company developing first-in-class small molecules with a focus on targeting the DNA repair pathway wanted to bolster its internal pipeline with additional...
Learn More

Commercial development plan for a mesenchymal stem cell therapy in acute GvHD

Challenge Our client was a leading UK Research Institute requiring assistance in assigning internal commercialisation funding to the most promising research groups within the University. Alacrita was...
Learn More

MHRA scientific advice for a UK PhII trial in Primary Sclerosing Cholangitis

Challenge Our client specialised in the development of proprietary monoclonal antibodies directed towards novel targets for the treatment of immune-mediated and fibrotic disorders, including orphan...
Learn More

New in-licensing opportunities

Challenge A pharmaceutical company that pioneered peptide pharmaceutical products, and a leader in reproductive medicine and women’s health, gastroenterology, and urology, had recently made the...
Learn More

Glioblastoma landscape

Challenge A stem cell research company had developed a target product profile (TPP) for a novel therapy for glioblastoma (GBM). The company asked Alacrita to conduct a comprehensive review of the GBM...
Learn More

Target product profile creation

Challenge A UK based privately-held biotechnology company developing and exploiting a proprietary technology platform for optimising and controlling gene therapy expression was looking to evolve its...
Learn More

European Payer Research

Challenge A privately held specialty pharmaceutical company focused in the field of psychiatry was conducting a Phase III clinical evaluation of its new formulation (one-per-day) of a commonly...
Learn More
1 2 3 4 5 ... 14
Next

Asset Partnering

Learn about our current partnering opportunities and submit your assets.

Learn More

Can we help?

Contact us to learn about how we can help support your needs.

Contact us

© 2019 Alacrita Holdings Limited   _

Alacrita Consulting Ltd
2 Royal College St,
London,
NW1 0NH

Registered in England & Wales.
No. 10530608

Alacrita Consulting Inc
303 Wyman Street,
Waltham,
MA 02451

Registered in Massachusetts.

Alacrita AG
Artherstrasse 7,
6300 Zug,
Switzerland

Registered in Switzerland.
No. CHE-233.138.008